While anti-PD-1 treatment alone effectively controlled B16 tumor growth in comparison to TGFβ monotherapy; the combination of anti-TGFβ1 with anti-PD-1 therapy was superior to either treatment alone in delaying tumor growth (Fig. 6c). The gene discussed is TGFB1; the disease is neoplasm.